- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. sophomore Avg
|
Exhibit 23.1
Consent of Independent Registered Public Accounting Firm
We consent to the incorporation by reference in the following Registration Statements:
| (1) | Registration Statement (Form S-1 No. 333-232332) of DelMar Pharmaceuticals, Inc. and in the related prospectus, |
| (2) | Registration Statement (Form S-1 No. 333-232931) of DelMar Pharmaceuticals, Inc. and in the related prospectus, |
| (3) | Registration Statement (Form S-3 No. 333-213600) of DelMar Pharmaceuticals, Inc. and in the related prospectus, and |
| (4) | Registration Statement (Form S-3 No. 333-229020) of DelMar Pharmaceuticals, Inc. and in the related prospectus; |
of our report dated September 9, 2019, with respect to the consolidated financial statements of Kintara Therapeutics, Inc. (formerly DelMar Pharmaceuticals, Inc.) included in this Annual Report (Form 10-K) of Kintara Therapeutics, Inc. for the year ended June 30, 2020.
Vancouver, Canada, | /s/ Ernst & Young LLP |
September 18, 2020 | Chartered Professional Accountants |